camostat – Page 3 – Communicable Diseases Research

A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19

건강한 성인을 대상으로 한 고용량 카모스타트 메실레이트에 대한 1상 연구는 COVID-19 치료를 위해 TMPRSS2 억제제를 용도 변경하는 근거를 제공합니다

Clinical Trial

Published on 2021-09-012022-09-11
Journal: Clinical and translational science [Category] 신약개발, 임상,

SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion

SPIKE-1: SARS-CoV-2 스파이크 단백질 개시 막 융합을 차단하여 COVID-19의 임상 진행을 줄이는 데 camostat의 사용을 평가하는 커뮤니티 환경에서의 무작위 2상/3상 시험

Letter

Published on 2021-08-192022-09-10
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 acute respiratory syndrome coronavirus apyrexia available data baseline best Biomarkers Blinding camostat clearance Clinical improvement clinical trial Community conducted control arm coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 symptom COVID-19 symptoms COVID-2019 Day defined Deterioration determined by diagnostics disease dissemination duration of illness Efficacy element eligibility criteria Eligible patients EudraCT evaluate Evidence evidence of Formal four times daily functional Guidance Health Organization health protection high risk hospital Hospital admission Hospital admissions Host include Infection initial Interactive Web Response System interim analysis Ireland IWRS Laboratory testing maximum membrane fusion moderate Mortality multicentre nasal negative swab number objective open open label Open-label Ordinal Scale outcome outcome measure overall mortality oxygen oxygen-free day Oxygenation participant Patient patient population patients with SARS-CoV-2 performed phase PK data Prevent primary care progression protection protocol provided Public Public Health Agency Public Health England qPCR questionnaire randomisation randomised randomised controlled trial receive recruit recruited recruitment reduce reducing refinement requiring supplemental oxygen Research respiratory risk RT-PCR Saliva Sample size Sample size calculations SARS-CoV-2 SARS-COV-2 infection secondary Secondary objective Secondary objectives secondary outcome measures serum antibody Severe acute respiratory syndrome severe acute respiratory syndrome coronavirus 2 severity spike status supplemental oxygen supplementary material supplementary oxygen supportive care Swab symptom severity tablets temperature the patient TMPRSS2 translational Translational research Treatment treatment arm Trial trial protocol Trial registration typical symptom typical symptoms upper respiratory Ventilation ventilator ventilator-free day Ventilator-free days Viral Viral load viral shedding website World Health Organization
[DOI] 10.1186/s13063-021-05461-9 PMC 바로가기 [Article Type] Letter

The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19

Research Article

Published on 2021-08-032022-10-29
Journal: mBio [Category] COVID-19, SARS,

[키워드] ACE2 acute respiratory syndrome Ad5-hACE2 airway epithelia angiotensin-converting enzyme 2 bind Calu-3 camostat Camostat mesylate caused Cell cell line cleaved coronavirus coronavirus disease COVID-19 disease pathogenesis entry of SARS-CoV-2 epithelia exhibiting greater hACE2 host cell human ACE2 in vivo Infection inhibit inhibitors initiate intranasal K18 K18-hACE2 limit lung tissue membrane fusion MERS-CoV mice Middle East Model morbidity and mortality Mortality mouse Mouse models nafamostat pandemic pathogenic coronavirus preclinical drug studies primary human airway Prophylactic protease Protease inhibitor protease TMPRSS2 Protective pulmonary receptor reduced respiratory syndrome coronavirus respiratory tract SARS-CoV-2 SARS-COV-2 infection serine protease serine protease inhibitors significantly Spike protein tested the spike protein TMPRSS2 transgenic mice Treatment viral burden weight loss
[DOI] 10.1128/mBio.00970-21 PMC 바로가기 [Article Type] Research Article

Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment

Article

Published on 2021-06-302022-10-29
Journal: International Journal of Molecular Sciences [Category] COVID-19, MERS,

Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat

Article

Published on 2021-06-232023-06-16
Journal: Journal of Virology [Category] MERS, SARS,

[키워드] camostat COVID-19 SARS-CoV-2 serine protease inhibitor TMPRSS2 uPA
[DOI] 10.1128/JVI.00861-21 PMC 바로가기

Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations

TMPRSS2 프로테아제와 Leupeptin의 강력한 결합은 SARS-CoV-2 용도 변경 약물에 대해 Camostat 및 Nafamostat의 대안이 될 수 있습니다: 분자 도킹 및 분자 역학 시뮬레이션에서 평가

Article

Published on 2021-06-012022-08-31
Journal: Applied biochemistry and biotechnology [Category] MERS, SARS, 신약개발, 치료제,

[키워드] Acute respiratory infection Amino acid amino acids bind binding binding affinity camostat Camostat mesylate caused clinical trial Complete complete cure coronavirus coronavirus SARS-CoV-2 COVID-19 COVID-19 disease docking study drug drug target drugs Dynamics evaluate form Host human cell humans Infection information inhibit inhibiting Interaction key amino acid key amino acids less leupeptin life MD simulation MD simulations molecular molecular docking molecular dynamics nafamostat outbreak performed protease reported Repurposed drug Repurposed drugs respiratory respiratory infection reveal RMSD RMSF SARS-CoV-2 SARS-CoV-2 virus SARS-CoV-2 virus infection Serine serine 2 Simulation stability Strong tested the SARS-CoV-2 virus TMPRSS2 TMPRSS2 protein transmembrane transmembrane protease serine 2 virus entry virus infection Wuhan Wuhan, China
[DOI] 10.1007/s12010-020-03475-8 PMC 바로가기 [Article Type] Article

Outcomes of patients with end stage kidney disease on dialysis with COVID-19 in Abu Dhabi, United Arab Emirates; from PCR to antibody

아랍에미리트 아부다비에서 코로나19 투석을 받은 말기 신장질환 환자의 결과; PCR에서 항체로

Research

Published on 2021-05-262022-09-01
Journal: BMC Nephrology [Category] SARS, 진단, 치료제,

[키워드] Abu addition age antibody Antibody Response Antibody responses Asymptomatic average average age camostat characteristics of patient Cohort combinations Community Comorbidities concerning Contact contributed cough country COVID 19 COVID-19 COVID-19 infection COVID19 Critical care defined demographics develop diabete diabetes dialysis disease drug End stage kidney disease examined family Favipiravir Haemodialysis heart disease Hydroxychloroquine hypertension ICU IgG antibody individual infected individual infected individuals Infection Ischaemic heart disease Isolation Kidney disease lack Local Lopinavir lower mortality majority male median time Mild Mild disease Mortality Most patients negative PCR test outcome overall mortality Patient patients PCR PCR positive patient PCR positivity PCR tests performed Population positive patient positive patients presenting symptoms Rapid required Result Ritonavir Screening screening strategy serology source of infection spread of COVID-19 steroid Steroids study period subset symptomatic tested the antibody response Tocilizumab Viral viral clearance was performed were used with COVID-19
[DOI] 10.1186/s12882-021-02378-y PMC 바로가기 [Article Type] Research

Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial

초기 SARS-CoV-2 Q-PCR 양성 고위험 개인(RES-Q-HR)의 회복기 혈장/카모스타트 메실레이트: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-05-172022-08-31
Journal: Trials [Category] SARS, 임상, 치료기술, 치료제,

[키워드] accommodation acts Administered administration Adult patients Adverse adverse events alcohol Alcohol Abuse ALT anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody anticancer Antiviral antiviral therapy appearance approved AST blinded Blinding BMI body weight Bone marrow Breastfeeding CAD camostat Camostat mesylate Capsule Care Caregivers Cell Child chronic Chronic kidney disease chronic obstructive pulmonary disease chronic obstructive pulmonary disease (COPD) cirrhosis CKD clinical clinical condition Compliance Concomitant concurrent conducted control group Controlled trial convalescent plasma COPD Coronary artery Coronary artery disease cough COVID-19 COVID-19 pneumonia criteria cumulative defined diabetes Diabetes Mellitus diagnosed diagnosis of SARS-CoV-2 diarrhea disease Disease progression disease stage disorder dissemination double-blind Duration early disease Early phase of SARS-CoV-2 infection Efficacy element enrolled Enrollment enrolment EudraCT evaluate evening event evidence of Exanthema excluded exclusion criteria fatigue Fever fibrosis Germany GFR half-live headache high risk higher risk Hospitalization Hospitalized host cell hypersensitivity IgA deficiency immunization Inclusion inclusion criteria increased risk independent individual Infection infection with SARS-CoV-2 Influenza influenza A Informed consent inhibitor institution intervention arm intervention arms Kidney disease less Life expectancy likelihood Liver cirrhosis Local local Ethics Committee Mask mesylate moderate mother multicenter nasal nasal cannula Neutralizing number objective Obstructive obstructive pulmonary disease Older Ordinal Scale organ outcome outcomes oxygen oxygen demand Pancreatitis parallel group participant Participants passive immunization Patient patients hospitalized PCR Placebo plasma Plasma transfusion Pneumonia positive pregnant women Presence Prevent prevent disease progression primary endpoint progression protocol pulmonary disease pulmonary fibrosis Q-PCR randomization Randomized Randomized controlled trial receive recruitment reduce Regulatory reported risk factor safety monitoring committee Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 PCR screening visit Serine serine protease TMPRSS2 Serious Adverse Event Serious Adverse Events severe COVID-19 Shortness of breath SOC sore throat Stage Standard Standard of care stratified Stress Study protocol supplementary material Symptom symptom duration Symptoms tertiary care center tested the cell titers TMPRSS2 transfusion reaction Treatment treatment arm Trial Trial registration Tumor typical symptom typical symptoms ULN virus website WHO with COVID-19 women working hypothesis written Informed Consent
[DOI] 10.1186/s13063-021-05181-0 PMC 바로가기 [Article Type] Letter

Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics

SARS-CoV-2에 의한 인터페론 길항작용: 역유전학을 이용한 기능적 연구

Article

Published on 2021-05-012022-09-11
Journal: The Lancet. Microbe [Category] Fulltext, SARS, 변종, 치료제,

[키워드] Activation acute respiratory syndrome adaptive Amino acid amino acid substitution amino acid substitutions amino acids analysed Analysis antagonistic backbone Bildung Calu Calu-3 cell calu-3 cells camostat camostat mesilate Cell cell entry cell line cellular entry receptor changes COVID-19 cytokine domain ENCODE Epidemic evaluate evaluated expressed fitness Frame functional gene induction Genes Genetic genetic engineering genetics homologous homology host cell host cells interfere interferon interferon antagonism interferon treatment interferon-stimulated gene interferon-stimulated genes investigated IRF3 less luciferase Mutagenesis mutant MX1 nuclear translocation Open reading frame ORF6 phenotype phenotypic Protein Replication residue residues RT-PCR SARS-CoV SARS-CoV-2 SARS-CoV-2 protein sensitivity Severe acute respiratory syndrome strain Strains suppressed TMPRSS2 transcription factor transmission efficiency Treatment type I interferon Vero E6 Vero E6 cell VERO E6 cells virus wild-type
[DOI] 10.1016/S2666-5247(21)00027-6 PMC 바로가기 [Article Type] Article

Computational Identification of a Putative Allosteric Binding Pocket in TMPRSS2

Molecular Biosciences

Published on 2021-04-302022-10-31
Journal: Frontiers in Molecular Biosciences [Category] COVID-19,